1. 200 A randomized, placebo-controlled study of galcanezumab in patients with treatment-resistant migraine: double-blind results from CONQUER. Issue 6 (27th May 2022) Authors: Mulleners, Wim; Kim, ByungKun; Láinez, Miguel; Lanteri-Minet, Michel; Aurora, Sheena; Nichols, Russell; Wang, Shufang; Tockhorn-Heidenreich, Antje; Pain, Andrew Journal: Journal of neurology, neurosurgery and psychiatry Issue: Volume 93:Issue 6(2022) Page Start: A70 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. OnabotulinumtoxinA for chronic migraine in Korea: 1-month postmarketing surveillance and phase 4 trial results. (25th December 2016) Authors: Kim, ByungKun; Kim, Manho; Chung, Chin-Sang; DeGryse, Ronald; Lai, Karen; Yushmanova, Irina; Lum, Arlene; Davar, Gudarz Journal: Toxicon Issue: Volume 123(2016) Supplement Page Start: S49 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗